According to latest Symphony Health Solutions Rx data, Zubsolv tablets market share (4-week rolling average) declined to 5.57 %. W/w market share declined by 0.14 percentage points to 5.52 %. Zubsolv TRx market share (4-week rolling average) was down to 5.65 %. Compared to last week the w/w market share declined by 0.16 percentage points to 5.54 %. The overall market (buprenorphine/naloxone products) shows a y/y growth rate of 7.5 % (4-week rolling average) and TRx a y/y growth rate of 8.6 % (4-week rolling average).